Trial Profile
A Prospective Single Institution Study of Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 29 Nov 2021 Status changed from recruiting to withdrawn prior to enrolment.
- 12 Apr 2011 New trial record